SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Versicor (VERS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (31)2/28/2003 3:51:26 PM
From: Arthur Radley  Read Replies (1) of 83
 
Merger effective as of tomorrow...one would have to admit that they will have a nice pipeline of "potential" drugs...

Operational Highlights
* Merger agreement of Biosearch with Versicor Inc. signed: the merger to
be effective from March 1, 2003;
* Versicor started Phase III studies of Dalbavancin for Skin and Soft
Tissue Infections;
* Versicor completed Phase II studies of Dalbavancin for Skin and Soft
Tissue Infections. The results, announced in September, confirmed the
clinical effectiveness of Dalbavancin, the first once-weekly injectable
antibiotic;
* Versicor started Phase II studies of Dalbavancin for Staphylococcal and
other serious Gram-positive infections;
* Enrollment for Phase I study of BI-K0376, the novel antibiotic for the
topical treatment of acne, completed;
* Rights for the nasal application of Ramoplanin for the treatment of
multiresistant Staphylococcus aureus carriers reacquired from
Intrabiotics Pharmaceuticals;
* Phase III clinical trial of Ramoplanin in the US by US licensee Genome
Therapeutics Corp. continuing to progress;
* Pre-clinical Research and Development activities continuing to
progress, to create a solid product pipeline;
* A 6.5 million Euro Innovation Technology Fund grant awarded by the
Italian government;
* Construction of the production plant in Pisticci (MT) continuing to
progress.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News